Xu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xu Wang has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Daniel John Siegwart
Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA
11 shared publications - Yehui Sun
Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA
9 shared publications Sumanta Chatterjee
Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA
8 shared publicationsXizhen Lian
Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA
7 shared publications- Yufen Xiao
Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA
7 shared publications - Lukas Farbiak
Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, University of Texas Southwestern Medical Center, Dallas, USA
6 shared publications
Latest Publications
- Open Access
- 23 August 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (59) , e74762
Esterified Cholesterol Conjugates Enable LNP‐Mediated mRNA Delivery to the Blood–Brain Barrier Following Intravenous Administration
The blood–brain barrier (BBB) plays a critical role in maintaining central nervous system homeostasis by regulating molecular and cellular exchange between the brain and peripheral circulation. While most delivery strategies focus on crossing the BBB, targeting brain endothelial cells directly may offer a complementary and more controlled alternative for therapeutic intervention. This study presents a ligand‐free lipid nanoparticle (LNP) platform that enables efficient mRNA delivery to the brain endothelium via systemic administration. A modular synthesis strategy was used to generate a chemically diverse library of cholesterol‐based lipids. Screening of 486 LNPs identified an optimized four‐component formulation consisting of C6O2B2 (novel cholesterol‐based lipid), DODAP, DSPC, and DMG‐PEG, which achieves high transfection efficiency in brain endothelial cells without the incorporation of free cholesterol or disruption of BBB integrity and function, such as those utilized in focused ultrasound (FUS) techniques. This BBB‐targeting LNP platform avoids neuronal and glial transfection, thereby offering a noninvasive, and scalable approach for cerebrovascular gene delivery. The work establishes a new class of cholesterol‐based lipids and provides a foundation for next‐generation RNA therapeutics targeting BBB‐associated diseases.
- 23 August 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (59) , e74762
Open AccessEsterified Cholesterol Conjugates Enable LNP‐Mediated mRNA Delivery to the Blood–Brain Barrier Following Intravenous Administration
The blood–brain barrier (BBB) plays a critical role in maintaining central nervous system homeostasis by regulating molecular and cellular exchange between the brain and peripheral circulation. While most delivery strategies focus on crossing the BBB, targeting brain endothelial cells directly may offer a complementary and more controlled alternative for therapeutic intervention. This study presents a ligand‐free lipid nanoparticle (LNP) platform that enables efficient mRNA delivery to the brain endothelium via systemic administration. A modular synthesis strategy was used to generate a chemically diverse library of cholesterol‐based lipids. Screening of 486 LNPs identified an optimized four‐component formulation consisting of C6O2B2 (novel cholesterol‐based lipid), DODAP, DSPC, and DMG‐PEG, which achieves high transfection efficiency in brain endothelial cells without the incorporation of free cholesterol or disruption of BBB integrity and function, such as those utilized in focused ultrasound (FUS) techniques. This BBB‐targeting LNP platform avoids neuronal and glial transfection, thereby offering a noninvasive, and scalable approach for cerebrovascular gene delivery. The work establishes a new class of cholesterol‐based lipids and provides a foundation for next‐generation RNA therapeutics targeting BBB‐associated diseases.
- 12 August 2026
- Published by Springer Nature in Nature Chemical Engineering
- Vol. 3 (8) , 443-459
Tunable polymers for polymer–lipid hybrid nanoparticles facilitate controlled organ-selective RNA delivery
- 12 August 2026
- Published by Springer Nature in Nature Chemical Engineering
- Vol. 3 (8) , 443-459
Tunable polymers for polymer–lipid hybrid nanoparticles facilitate controlled organ-selective RNA delivery
- Open Access
- 17 March 2026
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1-15
‘Tripod-like’ lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing
Developing lung-targeting delivery systems is essential for treating pulmonary conditions such as genetic respiratory diseases, infections, fibrosis and cancer. We synthesized and evaluated 444 lung-targeting lipids (LuT lipids) that form lipid nanoparticles (LNPs) to efficiently deliver messenger RNA and CRISPR–Cas9 genome editors to lungs with minimal side effects. Empirical analyses revealed structure–activity relationships, with top-performing LuT lipids possessing a unique ‘tripod-like’ structure consisting of a quaternary amine head, three long alkyl chains as legs and a short chain as a handle. LuT lipids improved endosomal escape, cargo release and endogenous targeting via adsorption of plasma proteins. Lead 1A7B13 LNPs showed a 25.5-fold improvement in mRNA delivery and a 9.2-fold increase in CRISPR–Cas9 gene-editing efficiency compared to benchmark DOTAP SORT LNPs, achieving over 90% selectivity to the lungs. 1A7B13 LNPs effectively delivered IL-10 mRNA in a therapeutic model of acute lung injury. This study reveals the relationship between lipid structure and lung-targeting activity, enriching the toolkit for lung-specific carriers.
- 17 March 2026
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1-15
Open Access‘Tripod-like’ lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing
Developing lung-targeting delivery systems is essential for treating pulmonary conditions such as genetic respiratory diseases, infections, fibrosis and cancer. We synthesized and evaluated 444 lung-targeting lipids (LuT lipids) that form lipid nanoparticles (LNPs) to efficiently deliver messenger RNA and CRISPR–Cas9 genome editors to lungs with minimal side effects. Empirical analyses revealed structure–activity relationships, with top-performing LuT lipids possessing a unique ‘tripod-like’ structure consisting of a quaternary amine head, three long alkyl chains as legs and a short chain as a handle. LuT lipids improved endosomal escape, cargo release and endogenous targeting via adsorption of plasma proteins. Lead 1A7B13 LNPs showed a 25.5-fold improvement in mRNA delivery and a 9.2-fold increase in CRISPR–Cas9 gene-editing efficiency compared to benchmark DOTAP SORT LNPs, achieving over 90% selectivity to the lungs. 1A7B13 LNPs effectively delivered IL-10 mRNA in a therapeutic model of acute lung injury. This study reveals the relationship between lipid structure and lung-targeting activity, enriching the toolkit for lung-specific carriers.
- 11 September 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (10) , 2181-2196
Mannose-Conjugated Cholesterol Containing Lipid Nanoparticles for Active Targeted mRNA Delivery to Liver Sinusoidal Endothelial and Kupffer Cells
Lipid nanoparticle (LNP) delivery of mRNA to specific cell types is a necessary task for the development of safe and effective medicines. LNP delivery to the liver is largely driven by the binding of serum ApoE to the LNP surface, followed by subsequent uptake in LDL receptor (LDL-R)-expressing hepatocytes, thereby reducing their utility in nonhepatocyte liver diseases. Herein, we developed an active targeting strategy to overcome this limitation by incorporating mannose-conjugated cholesterol into LNPs. Since cholesterol comprises about half of all molecules in LNPs, we reasoned that it could serve as a scaffold for active targeting. Mannosylated LNPs enhance uptake into liver sinusoidal endothelial cells (LSECs) and Kupffer cells over hepatocytes following intravenous administration in mice. This process correlated with the expression of mannose receptors (CD206) in LSECs and Kupffer cells, where significantly greater LNP uptake and functional mRNA delivery occurred in CD206+ cells. Higher activity and selectivity could be endowed by reducing the hydrophobic acyl chain length in poly(ethylene glycol) (PEG) lipids to induce faster PEG shedding in systemic circulation and increase LNP surface-accessible mannose, thereby increasing binding interactions with mannose receptors on CD206+ cells and subsequent LNP uptake. The results establish that cholesterol can be employed as a ligand carrier in LNPs for enriching mRNA delivery to specific cells in vivo. We anticipate that this general strategy of cholesterol modification can be extended to other ligands and cell types in the future.
- 11 September 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (10) , 2181-2196
Mannose-Conjugated Cholesterol Containing Lipid Nanoparticles for Active Targeted mRNA Delivery to Liver Sinusoidal Endothelial and Kupffer Cells
Lipid nanoparticle (LNP) delivery of mRNA to specific cell types is a necessary task for the development of safe and effective medicines. LNP delivery to the liver is largely driven by the binding of serum ApoE to the LNP surface, followed by subsequent uptake in LDL receptor (LDL-R)-expressing hepatocytes, thereby reducing their utility in nonhepatocyte liver diseases. Herein, we developed an active targeting strategy to overcome this limitation by incorporating mannose-conjugated cholesterol into LNPs. Since cholesterol comprises about half of all molecules in LNPs, we reasoned that it could serve as a scaffold for active targeting. Mannosylated LNPs enhance uptake into liver sinusoidal endothelial cells (LSECs) and Kupffer cells over hepatocytes following intravenous administration in mice. This process correlated with the expression of mannose receptors (CD206) in LSECs and Kupffer cells, where significantly greater LNP uptake and functional mRNA delivery occurred in CD206+ cells. Higher activity and selectivity could be endowed by reducing the hydrophobic acyl chain length in poly(ethylene glycol) (PEG) lipids to induce faster PEG shedding in systemic circulation and increase LNP surface-accessible mannose, thereby increasing binding interactions with mannose receptors on CD206+ cells and subsequent LNP uptake. The results establish that cholesterol can be employed as a ligand carrier in LNPs for enriching mRNA delivery to specific cells in vivo. We anticipate that this general strategy of cholesterol modification can be extended to other ligands and cell types in the future.
- 11 July 2025
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (8) , 4844-4852
Structure–Activity Relationship of Ionizable Lipids for siRNA and mRNA Lipid Nanoparticle Design
Lipid nanoparticles (LNPs) represent the most effective vehicle class identified to date for delivering RNA. A stronger understanding of the structure-activity relationships that govern successful mRNA delivery would enable the development of improved LNPs. Herein, ionizable lipids with high mRNA in vitro delivery efficacy among 465 lipids were selected to be evaluated for their in vivo activity and structure-activity relationship. Variations of these ionizable amino hydroxy and amino lipid families were synthesized, and 42 lipids were evaluated to study how chemical alterations of the carbon chain within the core influence LNP potency. To further understand the relationship between chemical structure and in vivo hepatic delivery potency, physicochemical properties including size, PDI, pKa, and buffering capacity were measured. Our evaluations revealed that both the pKa and buffering capacity may be valuable in predicting in vivo hepatic delivery based on lipid structures, expanding the range of acceptable LNP pKa to 6.2-7.4, and showed that the buffering capacity may help predict formulations for successful hepatic delivery of mRNA-LNPs. This study reiterates the importance of the chemical structure of the ionizable amino lipid for LNPs and highlights the intricacies of its relationship with the physical properties of LNPs. We anticipate that understanding the structure-activity relationship of ionizable lipids will be valuable for the continued rational design of ionizable amino lipids for the LNP delivery of small and large RNA cargoes.
- 11 July 2025
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (8) , 4844-4852
Structure–Activity Relationship of Ionizable Lipids for siRNA and mRNA Lipid Nanoparticle Design
Lipid nanoparticles (LNPs) represent the most effective vehicle class identified to date for delivering RNA. A stronger understanding of the structure-activity relationships that govern successful mRNA delivery would enable the development of improved LNPs. Herein, ionizable lipids with high mRNA in vitro delivery efficacy among 465 lipids were selected to be evaluated for their in vivo activity and structure-activity relationship. Variations of these ionizable amino hydroxy and amino lipid families were synthesized, and 42 lipids were evaluated to study how chemical alterations of the carbon chain within the core influence LNP potency. To further understand the relationship between chemical structure and in vivo hepatic delivery potency, physicochemical properties including size, PDI, pKa, and buffering capacity were measured. Our evaluations revealed that both the pKa and buffering capacity may be valuable in predicting in vivo hepatic delivery based on lipid structures, expanding the range of acceptable LNP pKa to 6.2-7.4, and showed that the buffering capacity may help predict formulations for successful hepatic delivery of mRNA-LNPs. This study reiterates the importance of the chemical structure of the ionizable amino lipid for LNPs and highlights the intricacies of its relationship with the physical properties of LNPs. We anticipate that understanding the structure-activity relationship of ionizable lipids will be valuable for the continued rational design of ionizable amino lipids for the LNP delivery of small and large RNA cargoes.
- 9 July 2025
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (8) , 4853-4868
Reducing Complexity in Lipid Nanoparticles: Three-Component Zwitterionic Amino Lipids for Targeted Extrahepatic mRNA Delivery
Simplicity and chemical expansion of lipid nanoparticles (LNPs) offer the potential for increased therapeutic benefit of mRNA vaccines and medicines. 3-Component Zwitterionic Amino Lipid (ZAL) LNPs offer simplicity and varied organ target scope, though there is a lack of chemical and formulation exploration with this class of lipids. Herein, we report the synthesis and evaluation of ZALs with improved biocompatibility, enhanced mRNA delivery efficacy, and extrahepatic organ-specific delivery through derivation at the secondary hydroxyl position with opivalate, chloride, bromide, and acetate. Evaluation of these novel ZAL molecules revealed organ-specific delivery trends, changes in delivery efficacy, and an engineering framework for chemically modifying lipid components that correlate with each specific chemical modification. Furthermore, the most efficacious ZAL derivative, which contains an acetate modification, displayed enhanced immune cell transfection in an organ-specific manner. This study provides a roadmap for reducing the complexity of LNPs by decreasing the number of lipid components in an LNP from the canonical 4 lipids to 3 lipids and expands the chemical scope of LNPs capable of mediating extrahepatic delivery.
- 9 July 2025
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (8) , 4853-4868
Reducing Complexity in Lipid Nanoparticles: Three-Component Zwitterionic Amino Lipids for Targeted Extrahepatic mRNA Delivery
Simplicity and chemical expansion of lipid nanoparticles (LNPs) offer the potential for increased therapeutic benefit of mRNA vaccines and medicines. 3-Component Zwitterionic Amino Lipid (ZAL) LNPs offer simplicity and varied organ target scope, though there is a lack of chemical and formulation exploration with this class of lipids. Herein, we report the synthesis and evaluation of ZALs with improved biocompatibility, enhanced mRNA delivery efficacy, and extrahepatic organ-specific delivery through derivation at the secondary hydroxyl position with opivalate, chloride, bromide, and acetate. Evaluation of these novel ZAL molecules revealed organ-specific delivery trends, changes in delivery efficacy, and an engineering framework for chemically modifying lipid components that correlate with each specific chemical modification. Furthermore, the most efficacious ZAL derivative, which contains an acetate modification, displayed enhanced immune cell transfection in an organ-specific manner. This study provides a roadmap for reducing the complexity of LNPs by decreasing the number of lipid components in an LNP from the canonical 4 lipids to 3 lipids and expands the chemical scope of LNPs capable of mediating extrahepatic delivery.
- Open Access
- 4 June 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (8) , 1320
Publisher Correction: High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
- 4 June 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (8) , 1320
Open AccessPublisher Correction: High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
- Top Cited Papers
- 28 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (11) , 1840-1851
High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
Messenger RNA lipid-nanoparticle-based therapies represent an emerging class of medicines for a variety of applications. However, anti-poly(ethylene glycol) (anti-PEG) antibodies generated by widely used PEGylated medicines and lipid nanoparticles hinder therapeutic efficacy upon repeated dosing. Here we report the chemical design, synthesis and optimization of high-density brush-shaped polymer lipids that reduce anti-PEG antibody binding to improve protein production consistency in repeated dosing. Brush-shaped polymer lipid parameters, including side chain length, degree of polymerization, anchor alkyl length and surface regimes on lipid nanoparticles modulate anti-PEG antibody binding affinity and control their blood circulation pharmacokinetics. Compared to widely used 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000, lipid nanoparticles containing brush-shaped polymer lipids generate superior therapeutic outcomes in protein replacement therapy and genome editing models, reformulating structure–activity guidelines for the design of PEG lipid substitutes. Overall, these findings contribute to the general effort in the development of lipid nanoparticles with low immunogenicity to overcome current roadblocks to nucleic acid medicines.
- 28 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (11) , 1840-1851
Top Cited PapersHigh-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
Messenger RNA lipid-nanoparticle-based therapies represent an emerging class of medicines for a variety of applications. However, anti-poly(ethylene glycol) (anti-PEG) antibodies generated by widely used PEGylated medicines and lipid nanoparticles hinder therapeutic efficacy upon repeated dosing. Here we report the chemical design, synthesis and optimization of high-density brush-shaped polymer lipids that reduce anti-PEG antibody binding to improve protein production consistency in repeated dosing. Brush-shaped polymer lipid parameters, including side chain length, degree of polymerization, anchor alkyl length and surface regimes on lipid nanoparticles modulate anti-PEG antibody binding affinity and control their blood circulation pharmacokinetics. Compared to widely used 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000, lipid nanoparticles containing brush-shaped polymer lipids generate superior therapeutic outcomes in protein replacement therapy and genome editing models, reformulating structure–activity guidelines for the design of PEG lipid substitutes. Overall, these findings contribute to the general effort in the development of lipid nanoparticles with low immunogenicity to overcome current roadblocks to nucleic acid medicines.
- 10 December 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (50) , 34733-34742
Isosteric 3D Bicyclo[1.1.1]Pentane (BCP) Core-Based Lipids for mRNA Delivery and CRISPR/Cas Gene Editing
Lipid nanoparticles (LNPs) are an essential component of messenger RNA (mRNA) vaccines and genome editing therapeutics. Ionizable amino lipids, which play the most crucial role in enabling mRNA to overcome delivery barriers, have, to date, been restricted to two-dimensional (2D) architectures. Inspired by improved physicochemical properties resulting from the incorporation of three-dimensionality (3D) into small-molecule drugs, we report the creation of 3D ionizable lipid designs through the introduction of bicyclo[1.1.1]pentane (BCP) core motifs. BCP-based lipids enabled efficient in vivo mRNA delivery to the liver and spleen with significantly greater performance over 2D benzene- and cyclohexane-based analogues. Notably, lead BCP-NC2-C12 LNPs mediated similar to 90% reduction in the PCSK9 serum protein level via CRISPR/Cas9 gene knockout, outperforming 2D controls and clinically used DLin-MC3-DMA LNPs at the same dose. Here, we introduce BCP-based designs with superior in vivo activity, thereby expanding the chemical scope of ionizable amino lipids from 2D to 3D and offering a promising avenue to improve mRNA and gene editing efficiency for the continued development of genetic medicines.
- 10 December 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (50) , 34733-34742
Isosteric 3D Bicyclo[1.1.1]Pentane (BCP) Core-Based Lipids for mRNA Delivery and CRISPR/Cas Gene Editing
Lipid nanoparticles (LNPs) are an essential component of messenger RNA (mRNA) vaccines and genome editing therapeutics. Ionizable amino lipids, which play the most crucial role in enabling mRNA to overcome delivery barriers, have, to date, been restricted to two-dimensional (2D) architectures. Inspired by improved physicochemical properties resulting from the incorporation of three-dimensionality (3D) into small-molecule drugs, we report the creation of 3D ionizable lipid designs through the introduction of bicyclo[1.1.1]pentane (BCP) core motifs. BCP-based lipids enabled efficient in vivo mRNA delivery to the liver and spleen with significantly greater performance over 2D benzene- and cyclohexane-based analogues. Notably, lead BCP-NC2-C12 LNPs mediated similar to 90% reduction in the PCSK9 serum protein level via CRISPR/Cas9 gene knockout, outperforming 2D controls and clinically used DLin-MC3-DMA LNPs at the same dose. Here, we introduce BCP-based designs with superior in vivo activity, thereby expanding the chemical scope of ionizable amino lipids from 2D to 3D and offering a promising avenue to improve mRNA and gene editing efficiency for the continued development of genetic medicines.
- Top Cited Papers
- 23 May 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (9) , 1409-1417
Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells
Therapeutic genome editing of haematopoietic stem cells (HSCs) would provide long-lasting treatments for multiple diseases. However, the in vivo delivery of genetic medicines to HSCs remains challenging, especially in diseased and malignant settings. Here we report on a series of bone-marrow-homing lipid nanoparticles that deliver mRNA to a broad group of at least 14 unique cell types in the bone marrow, including healthy and diseased HSCs, leukaemic stem cells, B cells, T cells, macrophages and leukaemia cells. CRISPR/Cas and base editing is achieved in a mouse model expressing human sickle cell disease phenotypes for potential foetal haemoglobin reactivation and conversion from sickle to non-sickle alleles. Bone-marrow-homing lipid nanoparticles were also able to achieve Cre-recombinase-mediated genetic deletion in bone-marrow-engrafted leukaemic stem cells and leukaemia cells. We show evidence that diverse cell types in the bone marrow niche can be edited using bone-marrow-homing lipid nanoparticles.
- 23 May 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (9) , 1409-1417
Top Cited PapersBone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells
Therapeutic genome editing of haematopoietic stem cells (HSCs) would provide long-lasting treatments for multiple diseases. However, the in vivo delivery of genetic medicines to HSCs remains challenging, especially in diseased and malignant settings. Here we report on a series of bone-marrow-homing lipid nanoparticles that deliver mRNA to a broad group of at least 14 unique cell types in the bone marrow, including healthy and diseased HSCs, leukaemic stem cells, B cells, T cells, macrophages and leukaemia cells. CRISPR/Cas and base editing is achieved in a mouse model expressing human sickle cell disease phenotypes for potential foetal haemoglobin reactivation and conversion from sickle to non-sickle alleles. Bone-marrow-homing lipid nanoparticles were also able to achieve Cre-recombinase-mediated genetic deletion in bone-marrow-engrafted leukaemic stem cells and leukaemia cells. We show evidence that diverse cell types in the bone marrow niche can be edited using bone-marrow-homing lipid nanoparticles.